Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
62 Leser
Artikel bewerten:
(0)

Clinical Therapeutics, Dietary Supplements and Aesthetic Solutions Propel the Anti-aging Market to Hit $85.6 Billion by 2022

Drug-as-a-service model leveraging big data analytics, multi-ingredient products and nanotechnology applications will create growth opportunities, finds Frost & Sullivan

SANTA CLARA, California, June 6, 2018 /PRNewswire/ -- The anti-aging industry is experiencing a paradigm shift toward embracing an age prevention-management-treatment continuum that is focused on health span rather than lifespan-driven metrics. This transformation will drive new growth opportunities for providers offering integrative solutions combining the three market segments-conventional therapies, dietary supplements, and aesthetic procedures, devices and products-delivered using digital enablers.

Frost & Sullivan, in partnership with A4M.com, has recently released its analysis, Anti-aging Therapies & Services Market-Trends & Growth Opportunities, which provides an assessment of trends, challenges, and growth opportunities tied to emerging anti-aging therapies and services. Business models, market dynamics, technology applications, and investment opportunities are also discussed. This market is forecast to reach $85.6 billion, growing at a compound annual growth rate (CAGR) of 6.5 percent from 2017 to 2022.

For further information on this analysis, please visit: http://frost.ly/2ip

Technologies that will be key enablers in the anti-aging market include:

  • Artificial Intelligence: AI-powered virtual assistant can help improve drug adherence as well as prevent adverse events. Additionally, AI-powered digital therapeutics will be crucial for driving digitally enabled customer engagement;
  • Big Data & Analytics: Drug-as-a-service models will require seamless access to and analysis of patient healthcare data and will drive pharmaceutical and technology company collaborations;
  • IoT & Cloud: Real-time telehealth/telemedicine applications, such as on-body trackers and diagnostic devices, will drive the need for IoT-enabled, cloud-based solutions; and
  • Mobile Devices: The widespread prevalence of mobile devices will boost the growth of applications based on solutions for drug adherence, activity monitoring, as well as virtual assistance.

"The industry's movement toward a 'prevent-manage-repair' approach to aging is creating opportunities for integrative methodologies for age management," said Neelotpal Goswami, Global Transformational Health Senior Industry Analyst at Frost & Sullivan. "Key technology trends such as the use of digital enablers and drug-as-a-service will drive pharmaceutical and technology company collaborations."

To benefit from these growth opportunities, savvy companies should:

  • Adopt novel pharmacological approaches that target specific drivers of aging, such as telomeres, rapalogs, senescent cells, and mitochondria-based therapies;
  • Develop regenerative medicine focused on cell and gene therapy;
  • Enhance dietary supplements,personalized genome-based diets and fasting-mimetic diets that offer clinically validated results;
  • Leverage digital therapeutics and digital pills powered by big data and analytics, artificial intelligence, cloud computing, and mobile technologies; and
  • Foster aesthetic solutions that offer long-term results with minimum discomfort.

"Aging is the result of multiple physical pathways and processes, making it complicated to manage. Additionally, regulations are a key challenge for the industry, with aging still not being recognized as a disease by regulatory bodies, making it difficult for companies to position their products and solutions," observed Goswami. "However, these multiple pathways offer opportunities for multi-pronged pharmacological approaches focused on areas such as telomeres and senescent cells, as well as the use of regenerative medicine."

Anti-aging Therapies & Services Market-Trends & Growth Opportunities is part of Frost & Sullivan's Transformation Health - Life Sciences Growth Partnership Service program.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

Anti-aging Therapies & Services Market-Trends & Growth Opportunities
MDB7_52

Contact:
Mariana Fernandez
Corporate Communications
P: +1 (210) 348 1012
E: Mariana.Fernandez@frost.com
http://ww2.frost.com
twitter: @FS_Healthcare
LinkedIn: Frost & Sullivan

© 2018 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.